tiprankstipranks
Cytokinetics announces EMA has validated MAA for aficamten
The Fly

Cytokinetics announces EMA has validated MAA for aficamten

Cytokinetics (CYTK) announced that the European Medicines Agency, EMA, has validated the Marketing Authorization Application, MAA, for aficamten, a next-in-class cardiac myosin inhibitor, for the treatment of obstructive hypertrophic cardiomyopathy, HCM. The MAA will now be reviewed by the Committee for Medicinal Products for Human Use, CHMP. “With regulatory filings for aficamten already under review in both the U.S. and China, the validation of the MAA marks an important milestone in bringing this potential medicine to even more patients with HCM worldwide,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. “We look forward to working with EMA in connection with their review of our application.”

Don't Miss Our Christmas Offers:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App